On 12 Nov 2026 Centene Corporation closed at $70.27, +70.8% this year; market cap $34.72bn, P/E 23.8.
Health Care · Managed Health Care · NYSE · United States
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.
| Market cap | $34.72bn |
| P/E (trailing) | 23.8 |
| EPS (TTM) | $2.96 |
| Beta | 1.08 |
| Dividend | $0.00 |
| Dividend yield | 0.00% |
| Ex-dividend date | — |
| Latest report | 27 Oct 2026 |
| Next earnings | 26 Jan 2027 |
| YTD | +70.8% |
| 1Y | +94.1% |
| 3Y | -0.9% |
| 5Y | -1.5% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $194.78bn | $-6.67bn | $4.32bn |
| 2024 | $163.07bn | $3.31bn | $-490.00m |
| 2023 | $154.00bn | $2.70bn | $7.25bn |
| 2022 | $144.55bn | $1.20bn | $5.26bn |
| 2021 | $125.98bn | $1.35bn | $3.29bn |
We publish no single base value for Centene Corporation. Our valuation methods put it between $41.45 and $154.45 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.